VR

Venkata Rao Chunduri

Active Director Director DIN 10202872
DIN 10202872 First appointment Jun 2023
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2023
Shareholding value •••• Premium profile

About Venkata Rao Chunduri

Data last updated:

Venkata Rao Chunduri is a Director at Vensura Pharma Institute Private Limited (since 2023). Vensura Pharma Institute Private Limited reported revenue of ₹14,370 (FY 2025).

DIN 10202872
Primary Designation Director
First Appointment 16 Jun 2023
Oldest Company Age 3 yrs
Largest company Vensura Pharma Institute Private Limited · ₹14,370 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Jun 20232023₹14,370 (FY 2025)Active

Board colleagues of Venkata Rao Chunduri

Directorship timeline

Open interactive timeline →
Vensura Pharma Institute Private Limited
Premium access

Shareholding and investment profile for Venkata Rao Chunduri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkata Rao Chunduri

Venkata Rao Chunduri currently holds 1 directorship: Vensura Pharma Institute Private Limited (Director, since 16 Jun 2023, revenue ₹14,370 (FY 2025)).

Venkata Rao Chunduri was first appointed on 16 Jun 2023 as Director at Vensura Pharma Institute Private Limited.

The current boards of Venkata Rao Chunduri's companies include Gottumukkala Yamuna Subbaraju (Vensura Pharma Institute Private Limited), Mallikarjuna Reddy Pudaka (Vensura Pharma Institute Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available